Liver allocation policy recently was modified to use the Model for End-Stage Liver Disease (MELD) for patients with chronic liver disease to stratify potential recipients according to risk for waitlist death. In this study, a retrospective cohort of 760 adult patients with chronic liver disease placed on the liver transplant waitlist between January 1995 and March 2001 and followed up for up to 74 months was studied to assess the ability of the MELD to predict mortality among waitlisted candidates and evaluate the prognostic importance of changes in MELD score over time. Serial MELD scores predicted waitlist mortality significantly better than baseline MELD scores or medical urgency status. Each unit of the 40-point MELD score was associated with a 22% increased risk for waitlist death (P C .001), whereas medical urgency status was not a significant independent predictor. For any given MELD score, the magnitude and direction of change in MELD score during the previous 30 days (AMELD) was a significant independent mortality predictor. Patients with MELD score increases greater than 5 points over 30 days had a threefold greater waitlist mortality risk than those for whom MELD scores increased more gradually (P < .0001). We conclude that mortality risk on the liver transplant waitlist is predicted more accurately by serial MELD score determinations than by medical urgency status or single MELD measurements. AMELD score over time reflects progression of liver disease and conveys important additional prognostic information that should be considered in the further evolution of national liver allocation policy. (Liver TranspZ2003;9:12-18.)
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Recent studies have documented the ability of a score based on a continuous disease severity scale to predict 3-month mortality in a cohort of patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures for the treatment of variceal hemorrhage in cirrhotic patients.5~~ Initially termed the Mayo TIPS Model, the investigators found four statistically significant mortality predictors in a multivariable Cox model. Three were readily obtainable laboratory values: serum bilirubin level, serum creatinine level, and prothrombin time international normalized ratio (INR). The fourth variable was cause of cirrhosis; nonalcoholic noncholestatic causes had increased mortality.
A regression equation with coefficients for each of the four variables was constructed.
In their second report, Kamath et a16 slightly modified their model (now termed the Model for End-Stage Liver Disease [MELD] ) and examined several patient populations to assess its generalizability to a range of patients with end-stage liver disease. Although promising, these studies relied on a MELD score determination at a single point in each patient's course and did not directly study a group of patients awaiting liver Liver Transplant Waitlist Mortulity Risk 13 transplantation. These studies did not address changes in mortality risk over time or the need to periodically reassess that risk during the longer times required for patients awaiting a donated liver. A recent report examined patients on the liver waitlist with severe disease (status 2a) and found that the MELD was a superior predictor of pretransplantation ventilator requirements and dialysis need compared with the CTP system.' Another study found that the MELD was highly predictive of pretransplantation mortality in status 2a patients.*
Given that liver allocation policy in the United States is targeted toward providing donated livers to patients with the greatest risk for waitlist mortality, analysis of updated MELD scores and mortality risk during the entire interval that patients are on the waitlist is an important step in the evaluation of the MELD as a basis for liver allocation. This is especially so given the recent institution of MELD-based allocation. In addition to information gained from using serial MELD scores, we hypothesized that the direction and magnitude of recent changes in MELD scores may be independently associated with mortality risk. We conducted the current study of waitlisted liver transplant candidates to examine these issues.
Methods

Study Design and Data Collection
The University of Michigan Institutional Review Board (Ann Arbor, MI) approved the study protocol. All adult liver transplant candidates at the University of Michigan Health System with chronic liver disease who were placed on the national Organ Procurement and Transplantation Network (OPTN) waitlist for the first time between January 1, 1995, and study closure on March 13, 2001 , were eligible for inclusion in the study. Patients with acute (fulminant) liver failure were excluded. Institutional databases were queried to acquire a data set consisting of age, sex, race, underlying liver disease, and date of placement on the waitlist.
Medical urgency status designation used the system in effect during the study period. Until July 1, 1997, statuses 2, 3, and 4 were used for candidates with chronic liver disease who required continuous hospitalization, continuous outpatient care, and intermittent outpatient care, respectively. As of July 1, 1997, a semiquantitative system based on CTP score was used. Status 4 patients were reassigned to status 3 (CTP score, 7 to lo). Status 2 was redefined. Status 2b required a CTP score of 10 or greater or 7 points plus specified complications. Status 2a was reserved for patients who developed life-threatening complications, required intensive care unit care, and had a life expectancy of 7 days or less. Each patient's initial waitlist medical urgency status and all subsequent changes were recorded until the earliest of transplantation, death, or continued presence on the waitlist on March 13, 200 1. For patients removed from the waitlist for reasons other than transplantation or death, we used data from medical records supplemented by query of the Social Security Administration Death Master File.9 Time at risk was extended up to 30 days from waitlist removal (not to exceed the study end date), and deaths within 30 days of removal were counted as waitlist deaths.
MELD Score Calculations
MELD scores were calculated using serum bilirubin level, serum creatinine level, and INR according to Kamath et a15
Baseline calculation required all three laboratory components within 14 days of placement on the waitlist. Subsequent MELD calculations were made whenever one or more laboratory components changed. Scores were rounded to the nearest tenth and multiplied by 10. Based on previous studies, the coefficient for disease cause was not used; laboratory inputs and MELD score limits were performed in accordance with the current O P T N liver allocation methods.10 Serum bilirubin, INR, or serum creatinine values less than 1.0 were set to 1.0 to preclude negative scores. Serum creatinine level was capped at 4.0. MELD scores were capped at 40.
Waitlist Survival Modeling
Odds of 90-day mortality were estimated using logistic regression. The concordance c-statistic (area under the receiver operating characteristic curve [AUC ROC]) also was generated. Time-dependent Cox proportional hazard regression models also were developed to assess mortality risk with censoring at transplantation. Models were adjusted for patient age, sex, race, and year of placement on the waitlist. Diagnosis was not significantly associated with mortality on the waitlist and thus was not included in regression models. Survival estimation was performed using SAS, version 8.00 (SAS Intitute, Cary, NC).
Changes in MELD Score Over 30-Day Intervals
The time-dependent Cox models describe mortality risk associated with a particular MELD score calculated at any time during the patient's residence on the waitlist. However, a patient's MELD score may change over time. T o determine whether proximate changes in MELD score influence waitlist mortality independent of the risk associated with the current MELD score itself, the slope of MELD scores during the 30 days before each MELD score was calculated using the least quares method, starting at day 30 on the waitlist (AMELD 
Validation of MELD Coefficients
Published parameter estimates for Cox model regression coefficients of the MELD equation (given previously) were compared with those calculated using laboratory values from the current study data set. 
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Results
Seven hundred sixty adult patients were placed on the waitlist for the first time between January l , 1995, and March 13,200 1, with follow-up during this same time. Table 1 lists demographic characteristics of the patient population. There was a preponderance of men (60%) and whites (85%). Mean age at baseline was 49 IT 9 years. The majority of patients had cirrhotic liver disease (78%) or cholestatic disorders (15%). During the course of the study, 258 patients (34%) received a liver transplant and 190 patients (25%) died on the waitlist. 
Validation of MELD Coefficients
Regression coefficients for log values of the three MELD components were statistically significant (P <
.OS) and within the 95% confidence bands for the original published coefficients (Fig. 1) .
Odds of 90-Day Mortality (Logistic Regression)
MELD scores 30 days after placement on the waitlist were used to estimate the odds of subsequent 90-day mortality (i.e., death on or before day 120). Compared with a reference group of patients with MELD scores between 0 and 10, survival among patients with higher MELD scores was significantly decreased ( Table 2 ).
The AUC ROC for this logistic regression model was 0.85. In a separate model, patients classified as status 2b and (old) status 2 after 30 days on the waitlist were at significantly increased risk for subsequent 90-day mortality compared with the status 3 reference group ( 
MELD Score and Waitlist Status as TimeDependent Covariates (Cox Models)
The relative risk (RR) for waitlist death was estimated using two separate Cox models. First, we examined the association of a single baseline MELD score on day 30 with waitlist death. Here, baseline MELD score was a significant mortality predictor (Chi-square, 88.8; R R , l . 15 per unit increase in MELD score; P < .001). In the second model, all available MELD scores during the patient's residence on the waitlist were used in a timedependent Cox model. Compared with baseline MELD score, the time-dependent MELD score was much more predictive ofwaitlist mortality (Chi-square, 630.6; RR, 1.22 per unit increase in MELD score; P < .OOl). In the time-dependent model, risk for death was associated with updated MELD scores, and each increase of one MELD point was associated with a 22% increase in waitlist mortality.
A separate time-dependent analysis also found that waitlist status was significantly associated with waitlist mortality risk ( Table 3) . Compared with status 3, status 2b was associated with a fivefold increase in risk, and status 2a, with an RR of 85.2 (P C .001).
Finally, MELD score and waitlist status were tested together as time-dependent covariates in a combined Cox regression model. As listed in Table 4 , MELD score was highly significant and associated with a waitlist mortality risk of 22% per unit increase in MELD score. Waitlist status provided no significant incremental contribution to risk for death after updated MELD scores were accounted for in the model. 
Change of MELD Score
To determine the effect of changes in MELD score over time for a given patient, the slope representing that change during the 30 previous days was studied (AMELD). The reference group for this analysis was composed of 30-day intervals in which modest changes from 0 to + 5 MELD score points were recorded, reflecting gradual worsening of liver disease in the waitlist population. Decreasing MELD scores (negative AMELD) during the 30-day interval (slope < 0) were associated with a slightly protective effect (slope < 0; RR, 0.76; P = 355; Fig. 2 ). Positive AMELD of more than 5 points during 30 days (slope > 5 ) was accompanied by a threefold greater risk for death compared with the reference group (slope > 5; RR, 3.16; P < .0001).
This effect was independent of and additive to the absolute MELD score at the end of each 30-day interval (current MELD; RR, 1.17; P < .001).
Discussion
Allocation of donor livers in the United States is guided primarily by assessment of the risk of recipient death in the absence of a transplant as part of the overall goal to maximize overall transplant benefit. Until February 2002, stratification of candidates used medical urgency statuses that divided patients into those with acute (status 1) and chronic (status 2a, 2b, and 3) liver disease.3 Medical criteria associated with disease severity were used to assign patients to the three chronic-disease status designations, and donor livers were allocated in descending order of status on a point system based on blood group type compatibility and waiting time within defined geographic areas (local Organ Procurement Organization [OPO] , OPTN region, entire nation).
Increasing recognition that, especially within statuses 2b and 3, wide variations exist in degree of medical urgency prompted the application of the MELD to liver allocation. In part, the MELD creates a more finely granular allocation system (40 levels) than the chronicdisease status system (3 levels). However, data concerning the ability of the MELD to accurately predict liver waitlist mortality during the prolonged periods that patients must wait for liver transplants has been lacking and will be some time forthcoming from the newly enacted national system.
Because the MELD was first developed as a tool to predict mortality after TIPS placement in cirrhotic patients, it is important to determine its predictive value for actual waitlisted patients who are awaiting liver transplantation. A recently published study showed that 3-month mortality could be predicted by the MELD in patients who had a range of chronic hepatic disorders.6 That study suggested the MELD is a generalizable tool for prognostication in such patients, but did not directly test that hypothesis on a population of waitlisted patients.
We found that baseline MELD scores were significantly associated with liver waitlist mortality and MELD scores were more predictive than medical status level. This supports previous work6 and is consistent with the direction in which national liver allocation policy has been evolving.
Unfortunately, a single MELD score determined at the time of placement on the waitlist is unlikely to accurately reflect mortality risk across a patient's entire residence on the list. Median waiting time for a liver transplant in the United States is greater than 1 year,* and the course of chronic liver disease is progressive and unpredictable. Thus, the new national system provides for periodic updates of MELD score for patients remaining on the waitlist. Availability of an existing longitudinal set of data in the current study provided three ways to validate and extend the utility of MELD score as a predictor of waitlist mortality and hopefully to preview some of the effects that may be expected under the new system.
First, the present study reports the first analysis of repeated MELD scores over time from patients on the liver transplant waitlist and provides strong evidence that updated MELD scores are a significantly better predictor of waitlist mortality than waitlist status levels or baseline (nonupdated) MELD scores. Patients in the cohort had a mean of 1 1 MELD determinations during Second, the Cox model based on University of Michigan data produced statistically significant and robust regression coefficients for each of the three laboratory components of the MELD score. In addition, these regression coefficients were within the estimated confidence bands for the original published coefficients. Because our cohort is different from all others on which MELD scores have been tested in the past, findings of this study provide further validation of the utility of the MELD in predicting pretransplantation mortality. Data collection from all waitlisted liver transplant candidates in the United States is under way, and subsequent analyses will determine whether adjustments to the coefficients are necessary over time.
Third, our analyses clearly show that AMELD, a measure of the magnitude and direction of change in MELD score during the previous 30 days, is an important and independent predictor of liver waitlist mortality. Patients with a positive AMELD greater than five during a 30-day period had more than a threefold greater waitlist mortality risk than patients for whom MELD scores increased more gradually. Patients with a AMELD of zero or negative AMELD during the preceding 30 days had slightly lower mortality risk compared with the reference group. Under the initial MELD-based liver allocation system currently implemented by the OPTN, allocation decisions among two or more candidates with the same MELD score are to be adjudicated by comparing the amount of waiting time at or above that score. Such patients would be likely to have a negative 30-day AMELD. In this circumstance, the existing tiebreaker rule may incorrectly order patients with the same MELD score. Thirty days ago, patient C had a MELD score of 10, and it increased to 15 two weeks ago before reaching its current level of 20. In this set of patients, the existing allocation system would offer the liver first to patient B (based on most time L 20) and then adjudicate between patients A and C solely on the basis of waiting time. However, the AMELD analysis suggests that patient C actually has the greatest predicted mortality risk on the basis of a positive AMELD of l0 points over 30 days. Patient A has a zero 30-day AMELD and therefore would be prioritized second under a AMELD mortality risk tiebreaker, and patient B would be third in line for the donor liver because of a negative AMELD. Further analyses using national data are critical to examine this issue and are under way. Incorporation of AMELD as a fourth component of a modified MELD score also should be considered.
There are some limitations to the present study. Most importantly, patterns of pretransplantation mortality and transplantation will change as the MELDbased system is used for organ allocation. All patients in the current study underwent transplantation under the existing medical status-based allocation system. Thus, censoring at transplantation would have affected a different set of patients had the available donor organs been allocated according to MELD score. For example, some patients with high MELD scores who died on the waitlist would likely have undergone transplantation, whereas patients with higher medical status with low MELD scores would have remained on the waitlist for a longer time. Despite this, the current study offers valuable insight into the effects of changing MELD scores over time in patients followed up longitudinally on the waitlist. It will take several years to accumulate similar longitudinal data at the national level.
We have considered a methodological issue that could arise because of nonrandom censoring because we try to perform transplantation in those at greatest risk for death and then censor them at transplantation in the analysis. If the sickest patients all received a transplant before death, then waitlist mortality rates clearly would be underestimated. However, under the allocation system before February 2002 for patients with chronic liver disease (statuses 2a, 2b, and 3), there are geographic distribution features that allocate donor organs within the local OPO area to lower risk patients, primarily on the basis of waiting time rather than severity. Regional and national patients at greater risk have lower priority than these local patients. In addition, a donor liver is not always available on a timely basis for the highest status persons on the waitlist. This results in substantial waitlist mortality for high-risk patients and, unfortunately, prevents them from receiving a trans-plant. These realities of the previous allocation system mitigate the effects of nonrandom censoring.
Pediatric candidates for liver transplantation were not included in the study because of lack of sufficient data. Children do not have the same risk for death on the waitlist as adults, and separate analyses have been developed using a Pediatric End-Stage Liver Disease SCOT^.^^,^^ Finally, patients with fulminant liver failure (status 1) also were excluded. The MELD score was developed for individuals with chronic liver disease, so we focused on these patients. Because the liver allocation system recently made operational by the OPTN retains status 1 as a separate allocation class and only uses MELD-based allocation for those with chronic disease, the use of MELD scores to assess mortality risk among status 1 patients will be possible once enough data have been collected at the national level.
